期刊文献+

痘苗病毒天坛株C8L—K3L片段缺失表达载体的生物学性能研究

Construction of expression vector of recombinant vaccinia virus TianTan strain with C8L-K3L region deletion and study on biological properties of the recombinant virus
原文传递
导出
摘要 目的研究缺失C8L.K3L片段的痘苗病毒天坛株载体的生物学性能及外源基因的免疫原性。方法构建缺失C8L-K3L区域的重组痘苗病毒天坛株载体VrITT△c8-K3-gag。在4种细胞上检钡0了重组载体的增殖能力、在小鼠和家兔模型上进行毒力评价,并在BALB/c小鼠进行了免疫效果评价。结果与Vrrr相比,VTTAC8-K3-gag在CEF、BHK-21、HeLa细胞中复制能力显著下降,在Vero细胞中失去复制能力。VTYAC8-K3-gag在小鼠和家兔模型中毒力均有显著降低。VTT△C8-K3-gag免疫小鼠第4周后诱导的痘苗病毒特异结合抗体与中和抗体滴度分别达到5.6×10^3和1.0×10^4,第9周滴度弦到5.8×10^5和5.25×10^3,与VTKgpe相比均显著下降3~9倍,但E3刺激后的细胞免疫应答无显著变化。VTT△C8-K3-gag单独免疫或与DNA疫苗联合免疫诱导的HIV特异性抗体水平和细胞免疫应答均与VTKgpe无差异。结论VTrAC8-K3-gag是一个安全性较高且具有深入研究价值的HIV候选疫苗株。 Objective To study the biological properties of the recombinant vaccinia virus Tiantan strain with CSL-K3L region deletion and its immunogenicity. Methods The expression vector of recombi- nant vaccinia virus TianTan strain ( VTTACS-K3-gag ) was constructed by replacing CSL-K3L genes with HIV gag gene and GFP gene. Viral replication capacities in chicken CEF, hamster BHK-21, monkey Vero and human HeLa cell lines were detected respectively. Virulence evaluation was carried out in mice and rab- bit models, and immune effects of VTTA CS-K3-gag was evaluated in BALA/c mice model. Results The replication capacity of VTrACS-K3-gag was impaired in chicken CEF, hamster BHK-21 and human HeLa cell lines, and was completely restricted in monkey Vero cell line as compared with the parental VTT. VTT A CS-K3-gag was less virulent than VTT in mice and rabbit models. The cellular and humoral responses to HIV elicited by VTFACS-K3-gag alone or in combination with DNA vaccine were similar to that induced by VTKgpe, while binding antibody responses specific to vaccinia viruse were reduced by 3-9 times, and neu- tralizing antibody response to VTT were reduced by 4-8 times. Conclusion The study suggests that VTT A CS-K3-gag is much safer than parental VTT and is a valuable strain for further studies on HIV-vaccine candidates.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2013年第6期434-439,共6页 Chinese Journal of Microbiology and Immunology
基金 国家科技重大专项(2012ZX10001-D08) 国家自然科学基金国际合作项目(81020108030) 传染病重点实验室归国人员启动经费(2011SKLID303) 中国疾控青年基金(2012A105)
关键词 痘苗病毒天坛株 VTT△C8-K3-gag 毒力 HIV 免疫应答 Vaccinia virus TianTan strain VTT ACS-K3-gag Virulence HIV Immune response
  • 相关文献

参考文献12

  • 1刘颖,段丹丽,彭虹,唐海丽,刘沙,张宁,王宁,刘建源,邵一鸣.HIV复制型痘苗病毒载体疫苗免疫原性分析[J].中华实验和临床病毒学杂志,2004,18(3):281-283. 被引量:9
  • 2Kennedy RB, Ovsyannikova 1G, Jacobson RM, et al. The immu- nology of smallpox vaccines. Curt Opin Immunol, 2009, 21 (3) : 314-320.
  • 3Reif DM, McKinney BA, Motsinger AA, et at. Genetic basis for adverse events after smallpox vaccination. J Infect Dis, 2008, 198 ( 1 ) : 16-22.
  • 4Umlauf BJ, Ovsyannikova IG, Haralambieva IH, et al. Correla- tions between vaccinia-specific immune responses within a cohort of armed forces members. Viral Immunol, 2011, 24 (5): 415- 420.
  • 5Moss B : Poxviridae : the viruses and their replicatiorr//Knipe DM, Howley PM. Fields Virology. Volume 2. Philadelphia: Lippincott Williams & Wilkins, 2007 : 2905-2946.
  • 6Kan S, Wang Y, Sun L, et al. Attenuation of vaccinia Tian Tan strain by removal of viral TC7L-TK2L and TA35R genes. PLoS One, 2012, 7(2): e31979.
  • 7Johnston JB, McFadden G. Poxvirus immunomodulatory strate- gies : current perspectives. J Virol, 2003, 77 ( 11 ) : 6093-6100.
  • 8Hinthong O, Jin XL, Shisler JL. Characterization of wild-type andmutant vaccinia virus M2L proteins' abilities to localize to the en- doplasmic reticulum and to inhibit NF-kappaB activation during in- fection. Virology, 2008, 373(2): 248-262.
  • 9Perrakis A, Morris R, Lamzin VS. Automated protein model building combined with iterative structure refinement. Nat Struct Biol, 1999, 6(5): 458-463.
  • 10Meng X, Chao J, Xiang Y. Identification from diverse mammali- an poxvimses of host-range regulatory genes functioning equiva- lently to vaccinia virus C7L. Virology, 2008, 372 ( 2 ) : 372- 383.

二级参考文献7

  • 1肖瑶,韩春卉,倪莉,谷淑燕.表达2型单纯疱疹病毒糖蛋白D的重组痘苗病毒对动物的免疫效果[J].中华实验和临床病毒学杂志,1995,9(3):246-249. 被引量:1
  • 2中华人民共和国卫生部 联合国艾滋病中国专题组.中国艾滋病防治联合评估报告[R].北京:中华人民共和国卫生部,2003.8-10.
  • 3Fenner F, Henderson DA, Arita I, et al. Smallpox and its eradication. Geneva: WHO, 1988. 2-3.
  • 4Feery BJ. Adverse reactions after smallpox vaccination. Med J Aust, 1977, 2: 180-183.
  • 5Gomez CE, Rodriguez D, Rodriguez JR, et al. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector. Vaccine, 2002, 20: 961-997.
  • 6Egan MA, Pavlat WA, Tartaglia J, et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte responses in seronegative adults by a non-replicating, host-range-restricted canarypox vector(ALVAC) carrying the HIV-1 MN env gene. J Infect Dis, 1995, 171:1623-1627.
  • 7薛绍礼,皮国华,谷淑燕,李平.表达Epstein-Barr病毒壳抗原gp125重组痘苗病毒的免疫原性[J].中国药理学通报,1999,15(3):263-265. 被引量:2

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部